Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9964)
All Articles published online
|
Publishing Process of This Article
|
Aug 10, 2014 (publication date) through Apr 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhao M, Ramaswamy B. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. World J Clin Oncol 2014; 5(3): 248-262 [PMID: 25114842 DOI: 10.5306/wjco.v5.i3.248] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v5/i3/248.htm |
| Number | Citing Articles |
| 1 |
Laila S. Agrawal, Ingrid A. Mayer. Optimizing the Use of Neoadjuvant Endocrine Therapy. Current Oncology Reports 2015; 17(7) doi: 10.1007/s11912-015-0455-z
|
| 2 |
Penn Muluhngwi, Carolyn M Klinge. Roles for miRNAs in endocrine resistance in breast cancer. Endocrine-Related Cancer 2015; 22(5): R279 doi: 10.1530/ERC-15-0355
|
| 3 |
Banita Thakur, Yashwant Kumar, Alka Bhatia. Programmed necrosis and its role in management of breast cancer. Pathology - Research and Practice 2019; 215(11): 152652 doi: 10.1016/j.prp.2019.152652
|
| 4 |
Tea Lanišnik Rižner, Theresia Thalhammer, Csilla Özvegy-Laczka. The Importance of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers. Frontiers in Pharmacology 2017; 8 doi: 10.3389/fphar.2017.00346
|
| 5 |
I. A. Voutsadakis. HER2 in stemness and epithelial–mesenchymal plasticity of breast cancer. Clinical and Translational Oncology 2019; 21(5): 539 doi: 10.1007/s12094-018-1961-x
|
| 6 |
Jyotsana Singhal, Shireen Chikara, David Horne, Ravi Salgia, Sanjay Awasthi, Sharad S. Singhal. 2′‐Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76. Molecular Carcinogenesis 2018; 57(12): 1751 doi: 10.1002/mc.22894
|
| 7 |
Inês Soares de Pinho, Catarina Abreu, Inês Gomes, Sandra Casimiro, Teresa Raquel Pacheco, Rita Teixeira de Sousa, Luís Costa. Exploring new pathways in endocrine-resistant breast cancer. Exploration of Targeted Anti-tumor Therapy 2022; : 337 doi: 10.37349/etat.2022.00086
|
| 8 |
Gül A. Başaran, Chris Twelves, Véronique Diéras, Javier Cortés, Ahmad Awada. Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treatment Reviews 2018; 63: 144 doi: 10.1016/j.ctrv.2017.12.002
|
| 9 |
Luke Piggott, Andreia Silva, Timothy Robinson, Angelica Santiago-Gómez, Bruno M. Simões, Michael Becker, Iduna Fichtner, Ladislav Andera, Philippa Young, Christine Morris, Peter Barrett-Lee, Fouad Alchami, Marco Piva, Maria dM. Vivanco, Robert B. Clarke, Julia Gee, Richard Clarkson. Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP. Clinical Cancer Research 2018; 24(10): 2452 doi: 10.1158/1078-0432.CCR-17-1381
|
| 10 |
Yuan-Ching Chang, Kun-Ming Rau, Dar-Ren Chen, Tsu-Yi Chao, Ming-Feng Hou, Chiun-Sheng Huang. Safety and efficacy of everolimus plus exemestane in postmenopausal women with treatment-refractory hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis from EVEREXES Taiwan subset. Journal of Cancer Research and Practice 2023; 10(3): 94 doi: 10.4103/ejcrp.eJCRP-D-23-00008
|
| 11 |
Salah A. Sheweita, Rania G. Ammar, Sally A. Sabra, Ahmed S. Sultan. Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells. Journal of Taibah University Medical Sciences 2021; 16(1): 112 doi: 10.1016/j.jtumed.2020.10.017
|
| 12 |
Samra Khalid, Rumeza Hanif, Samar H.K. Tareen, Amnah Siddiqa, Zurah Bibi, Jamil Ahmad. Formal modeling and analysis of ER-αassociated Biological Regulatory Network in breast cancer. PeerJ 2016; 4: e2542 doi: 10.7717/peerj.2542
|
| 13 |
Gilead Ebiegberi Forcados, Dorcas Bolanle James, Abdullahi Balarabe Sallau, Aliyu Muhammad, Peace Mabeta. Oxidative Stress and Carcinogenesis: Potential of Phytochemicals in Breast Cancer Therapy. Nutrition and Cancer 2017; 69(3): 365 doi: 10.1080/01635581.2017.1267777
|
| 14 |
Samra Khalid, Rumeza Hanif, Ishrat Jabeen, Qaisar Mansoor, Muhammad Ismail, Aamir Ahmad. Pharmacophore modeling for identification of anti-IGF-1R drugs and in-vitro validation of fulvestrant as a potential inhibitor. PLOS ONE 2018; 13(5): e0196312 doi: 10.1371/journal.pone.0196312
|
| 15 |
Florian Lüke, Dennis Christoph Harrer, Pan Pantziarka, Tobias Pukrop, Lina Ghibelli, Christopher Gerner, Albrecht Reichle, Daniel Heudobler. Drug Repurposing by Tumor Tissue Editing. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.900985
|
| 16 |
M.Yu. Shkurnikov, A.D. Kaprin. The role of interactomic interactions in tamoxifen-resistant breast cancer: new approaches to searching for the mechanisms of pathogenesis. Onkologiya. Zhurnal imeni P.A.Gertsena 2020; 9(6): 80 doi: 10.17116/onkolog2020906180
|
| 17 |
Girish Chandra Arya, Mohammad Khalid, Shefali Mehla, Vikash Jakhmola. A review of synthetic strategy, SAR, docking, simulation studies, and mechanism of action of isoxazole derivatives as anticancer agents. Journal of Biomolecular Structure and Dynamics 2023; : 1 doi: 10.1080/07391102.2023.2220819
|
| 18 |
Chao Dong, Jiao Wu, Yin Chen, Jianyun Nie, Ceshi Chen. Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.628690
|
| 19 |
Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells. Scientific Reports 2016; 6(1) doi: 10.1038/srep28004
|
| 20 |
Phungern Khongthong, Antonia K Roseweir, Joanne Edwards. The NF-KB pathway and endocrine therapy resistance in breast cancer. Endocrine-Related Cancer 2019; 26(6): R369 doi: 10.1530/ERC-19-0087
|
| 21 |
Chun-Yu Liu, Chia-Yun Wu, Karineh Petrossian, Tzu-Ting Huang, Ling-Ming Tseng, Shiuan Chen. Treatment for the endocrine resistant breast cancer: Current options and future perspectives. The Journal of Steroid Biochemistry and Molecular Biology 2017; 172: 166 doi: 10.1016/j.jsbmb.2017.07.001
|
| 22 |
Jun Yamamura, Yukiko Miyamura, Shunji Kamigaki, Junya Fujita, Hiroki Osato, Hironobu Manabe, Yumiko Tanaka, Wataru Shinzaki, Yukihiko Hahimot, Toshikazu Ito, Yoshifumi Komoike. Relationship between endocrine resistance and the periods of adjuvant endocrine treatment for hormone receptor-positive, HER2-negative breast cancer. Breast Disease 2021; 41(1): 109 doi: 10.3233/BD-210027
|
| 23 |
Shyambabu Chaurasiya, Yuman Fong. Viroimmunotherapy for breast cancer: promises, problems and future directions. Cancer Gene Therapy 2021; 28(7-8): 757 doi: 10.1038/s41417-020-00265-6
|
| 24 |
Marissa Meegdes, Marleen G. A. M. van der Velde, Sandra M. E. Geurts, Maartje A. C. E. van Kats, M. Wouter Dercksen, Vivianne C. G. Tjan-Heijnen. Case series of metastatic breast cancer patients with visceral crisis treated with CDK4/6 inhibitors. Journal of Chemotherapy 2023; : 1 doi: 10.1080/1120009X.2023.2279831
|
| 25 |
SILKE KAULFUSS, ANNA-MARIA HERR, ANJA BÜCHNER, BERNHARD HEMMERLEIN, ANDREAS R. GÜNTHERT, PETER BURFEIND. Leupaxin is expressed in mammary carcinoma and acts as a transcriptional activator of the estrogen receptor α. International Journal of Oncology 2015; 47(1): 106 doi: 10.3892/ijo.2015.2988
|
| 26 |
Federico Rojo, Abel González-Pérez, Jessica Furriol, Ma Jesús Nicolau, Jaime Ferrer, Octavio Burgués, MohammadA Sabbaghi, Irene González-Navarrete, Ion Cristobal, Laia Serrano, Sandra Zazo, Juan Madoz, Sonia Servitja, Ignasi Tusquets, Joan Albanell, Ana Lluch, Ana Rovira, Pilar Eroles. Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma. British Journal of Cancer 2016; 115(3): 322 doi: 10.1038/bjc.2016.204
|
| 27 |
Yujuan Kang. Landscape of NcRNAs involved in drug resistance of breast cancer. Clinical and Translational Oncology 2023; 25(7): 1869 doi: 10.1007/s12094-023-03189-3
|
| 28 |
Jacques Bonneterre, Jacques Bosq, Philippe Jamme, Alexander Valent, Erard M. Gilles, Alexander A. Zukiwski, Suzanne A.W. Fuqua, Carol A. Lange, Joyce O'Shaughnessy. Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort. ESMO Open 2016; 1(4): e000072 doi: 10.1136/esmoopen-2016-000072
|
| 29 |
Claudia Paret, Petra Simon, Kirsten Vormbrock, Christian Bender, Anne Kölsch, Andrea Breitkreuz, Özlem Yildiz, Tana Omokoko, Stefanie Hubich-Rau, Christoph Hartmann, Sabine Häcker, Meike Wagner, Diana Barea Roldan, Abderaouf Selmi, Özlem Türeci, Ugur Sahin. CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer. Oncotarget 2015; 6(28): 25356 doi: 10.18632/oncotarget.4516
|
| 30 |
Jinkyoung Kim, Jiyun Lee, Chungyeul Kim, Jinhyuk Choi, Aeree Kim. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells. Tumor Biology 2016; 37(5): 5811 doi: 10.1007/s13277-015-4440-9
|
| 31 |
Xinfeng Yu, Aiping Luo, Yicong Liu, Shuqing Wang, Ye Li, Wenna Shi, Zhihua Liu, Xianjun Qu. MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy. Molecular Cancer 2015; 14(1) doi: 10.1186/s12943-015-0480-4
|
| 32 |
S R Ande, K H Nguyen, G P Padilla-Meier, B L G Nyomba, S Mishra. Expression of a mutant prohibitin from the aP2 gene promoter leads to obesity-linked tumor development in insulin resistance-dependent manner. Oncogene 2016; 35(34): 4459 doi: 10.1038/onc.2015.501
|
| 33 |
Donita Africander, Karl-Heinz Storbeck. Steroid metabolism in breast cancer: Where are we and what are we missing?. Molecular and Cellular Endocrinology 2018; 466: 86 doi: 10.1016/j.mce.2017.05.016
|
| 34 |
Lufeng Zheng, Xia Meng, Xiaoman Li, Yan Zhang, Cheng Li, Chenxi Xiang, Yingying Xing, Yufeng Xia, Tao Xi. miR‐125a‐3p inhibits ERα transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor–positive breast cancer. The FASEB Journal 2018; 32(2): 588 doi: 10.1096/fj.201700461RR
|
| 35 |
Penn Muluhngwi, Abirami Krishna, Stephany L. Vittitow, Joshua T. Napier, Kirsten M. Richardson, Mackenzie Ellis, Justin L. Mott, Carolyn M. Klinge. Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells. Cancer Letters 2017; 388: 230 doi: 10.1016/j.canlet.2016.12.007
|
| 36 |
David Wilson, Glen Boyle, Lachlan McIntyre, Matthew Nolan, Peter Parsons, Jennifer Smith, Leon Tribolet, Alex Loukas, Michael Liddell, Lachlan Rash, Norelle Daly. The Aromatic Head Group of Spider Toxin Polyamines Influences Toxicity to Cancer Cells. Toxins 2017; 9(11): 346 doi: 10.3390/toxins9110346
|
| 37 |
Carolyn M. Klinge. miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets. Molecular and Cellular Endocrinology 2015; 418: 273 doi: 10.1016/j.mce.2015.01.035
|
| 38 |
Sumei Gao, Xiaoyan Li, Xia Ding, Liyu Jiang, Qifeng Yang. Huaier extract restrains the proliferative potential of endocrine-resistant breast cancer cells through increased ATM by suppressing miR-203. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-07550-9
|
| 39 |
Hang Liu, Jingxuan Wang, Minghui Zhang, Qijia Xuan, Zhipeng Wang, Xin Lian, Qingyuan Zhang. Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients. Breast Cancer Research and Treatment 2017; 166(1): 95 doi: 10.1007/s10549-017-4394-2
|
| 40 |
Elpetra P. M. Timmermans-Sprang, Ana Gracanin, Jan A. Mol. Molecular Signaling of Progesterone, Growth Hormone, Wnt, and HER in Mammary Glands of Dogs, Rodents, and Humans: New Treatment Target Identification. Frontiers in Veterinary Science 2017; 4 doi: 10.3389/fvets.2017.00053
|
| 41 |
Paolo Pronzato. Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer. Future Oncology 2017; 13(16): 1371 doi: 10.2217/fon-2017-0098
|